|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.08 USD | -0.29% |
|
+14.57% | +39.84% |
| 24/05 | JPMorgan Adjusts Price Target on Cellebrite DI to $14 From $12, Maintains Overweight Rating | MT |
| 24/05 | Deutsche Bank Adjusts Price Target on Cellebrite to $15 From $13, Maintains Buy Rating | MT |
Cellebrite DI Ltd. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 89.58 million compared to USD 71.23 million a year ago. Net loss was USD 71.37 million compared to USD 40.61 million a year ago.
Basic loss per share from continuing operations was USD 0.36 compared to USD 0.21 a year ago. Diluted loss per share from continuing operations was USD 0.36 compared to USD 0.21 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +39.84% | 248.56Cr | |
| +17.69% | 3,28900Cr | |
| +14.62% | 9.04TCr | |
| +14.59% | 8.56TCr | |
| +37.27% | 5.25TCr | |
| -20.13% | 5.03TCr | |
| +32.93% | 4.68TCr | |
| +83.75% | 4.27TCr | |
| -32.70% | 4.17TCr | |
| -1.24% | 2.78TCr |
CELLEBRITE DI LTD. 
